Trial 0S-23-3


PhI-138 / NCI 10509: A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination with the CDK4/6 Inhibitor Abemaciclib in Patients with NUT Carcinoma and Other Solid Tumors

Type: Treatment
Phase: Phase I
Status: Open to Accrual
Treatments: Biological Response Modifier, Immunotherapy
Randomized: No
USC Satellite Location: USC Koreatown, USC Newport Beach Oncology
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Robert Hsu, M.D.
Other Trial Staff:  Kristy Sartor Massopust, Coordinator, Sreebharathy Venkatesh, D.M., Sana Mutalib, Coordinator, Andrew Zeng, Coordinator, Thomas Won, Coordinator, Bomi Choi, Coordinator, Sophia Marmolejo, Coordinator, Sandy Tran, Coordinator, Azucena Vera, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.